Buys | $0 | 0 | 0 |
Sells | $9,230,325 | 20 | 100 |
Yamagishi-Dressler Tomoko | Chief Marketing Officer | 0 | $0 | 1 | $89,251 | $-89,251 |
GILL DAVID N | director | 0 | $0 | 2 | $131,010 | $-131,010 |
Parschauer Karah Herdman | director | 0 | $0 | 1 | $167,465 | $-167,465 |
Beaver Sandra | Chief Financial Officer | 0 | $0 | 4 | $176,078 | $-176,078 |
Avelar Rui | See Remarks | 0 | $0 | 3 | $452,549 | $-452,549 |
Malik Vikram | director | 0 | $0 | 2 | $459,215 | $-459,215 |
MOATAZEDI DAVID | See Remarks | 0 | $0 | 7 | $7.75M | $-7.75M |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Over the last 12 months, insiders at Evolus, Inc. have bought $0 and sold $9.23M worth of Evolus, Inc. stock.
On average, over the past 5 years, insiders at Evolus, Inc. have bought $3.4M and sold $18.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 174,967 shares for transaction amount of $1.3M was made by Malik Vikram (director) on 2023‑08‑15.
2025-03-12 | Sale | Parschauer Karah Herdman | director | 12,888 0.0196% | $12.99 | $167,465 | -2.53% | |
2024-12-23 | Sale | MOATAZEDI DAVID | See Remarks | 10,502 0.0167% | $10.85 | $113,967 | +24.08% | |
2024-12-23 | Sale | Avelar Rui | See Remarks | 2,252 0.0036% | $10.85 | $24,438 | +24.08% | |
2024-12-23 | Sale | Beaver Sandra | Chief Financial Officer | 1,586 0.0025% | $10.85 | $17,211 | +24.08% | |
2024-09-06 | Sale | Beaver Sandra | Chief Financial Officer | 3,276 0.0053% | $14.98 | $49,074 | -4.69% | |
2024-08-30 | Sale | Yamagishi-Dressler Tomoko | Chief Marketing Officer | 5,631 0.0089% | $15.85 | $89,251 | -11.39% | |
2024-06-06 | Sale | MOATAZEDI DAVID | See Remarks | 175,940 0.2852% | $12.59 | $2.21M | +8.19% | |
2024-06-05 | Sale | MOATAZEDI DAVID | See Remarks | 155,278 0.2465% | $12.92 | $2.01M | +3.15% | |
2024-06-04 | Sale | MOATAZEDI DAVID | See Remarks | 140,214 0.2217% | $12.73 | $1.78M | +3.89% | |
2024-06-03 | Sale | Malik Vikram | director | 7,500 0.0119% | $12.96 | $97,203 | +2.31% | |
2024-05-14 | Sale | GILL DAVID N | director | 6,718 0.0106% | $12.60 | $84,654 | +3.11% | |
2024-05-13 | Sale | Malik Vikram | director | 28,000 0.0459% | $12.93 | $362,012 | +4.36% | |
2024-05-13 | Sale | GILL DAVID N | director | 3,643 0.0059% | $12.72 | $46,356 | +4.36% | |
2024-05-10 | Sale | MOATAZEDI DAVID | See Remarks | 16,051 0.0256% | $12.72 | $204,127 | +3.06% | |
2024-05-10 | Sale | Avelar Rui | See Remarks | 3,441 0.0055% | $12.72 | $43,761 | +3.06% | |
2024-05-10 | Sale | Beaver Sandra | Chief Financial Officer | 2,423 0.0039% | $12.72 | $30,814 | +3.06% | |
2024-03-27 | Sale | MOATAZEDI DAVID | See Remarks | 6,236 0.01% | $13.86 | $86,431 | -6.36% | |
2024-03-19 | Sale | MOATAZEDI DAVID | See Remarks | 96,566 0.1564% | $13.92 | $1.34M | -5.87% | |
2024-03-19 | Sale | Avelar Rui | See Remarks | 27,603 0.0447% | $13.92 | $384,350 | -5.87% | |
2024-03-19 | Sale | Beaver Sandra | Chief Financial Officer | 5,672 0.0092% | $13.92 | $78,978 | -5.87% |
Malik Vikram | director | 246514 0.3877% | $3.25M | 4 | 7 | +1.4% |
GILL DAVID N | director | 33964 0.0534% | $448,324.80 | 2 | 3 | +8.2% |
Medytox Inc. | 3381326 5.3177% | $44.63M | 15 | 9 | <0.0001% | |
Jafar Michael M. | See Remarks | 174851 0.275% | $2.31M | 1 | 1 | <0.0001% |
BLANK SIMONE | 54881 0.0863% | $724,429.20 | 3 | 0 | <0.0001% |
$910,099,463 | 123 | 11.52% | $2.63B | |
$187,390,806 | 89 | 12.63% | $777.44M | |
$12,681,496 | 70 | 20.90% | $804.92M | |
$14,599,168 | 59 | 12.79% | $1.36B | |
$129,489,279 | 57 | 26.09% | $635.41M |
Increased Positions | 82 | +44.32% | 6M | +12.88% |
Decreased Positions | 75 | -40.54% | 5M | -9.54% |
New Positions | 26 | New | 2M | New |
Sold Out Positions | 27 | Sold Out | 999,404 | Sold Out |
Total Postitions | 192 | +3.78% | 52M | +3.35% |
Perceptive Advisors Llc | $75,078.00 | 8.17% | 5.15M | -210,776 | -3.94% | 2024-12-31 |
Tang Capital Management Llc | $72,912.00 | 7.93% | 5M | +150,000 | +3.09% | 2024-12-31 |
Blackrock, Inc. | $63,684.00 | 6.93% | 4.36M | +134,747 | +3.19% | 2024-12-31 |
Vanguard Group Inc | $46,271.00 | 5.03% | 3.17M | -23,927 | -0.75% | 2024-12-31 |
Nantahala Capital Management, Llc | $45,669.00 | 4.97% | 3.13M | +305,300 | +10.81% | 2024-12-31 |
Caligan Partners Lp | $39,282.00 | 4.27% | 2.69M | +498,900 | +22.75% | 2024-12-31 |
State Street Corp | $20,752.00 | 2.26% | 1.42M | +144,528 | +11.31% | 2024-12-31 |
Millennium Management Llc | $19,965.00 | 2.17% | 1.37M | +338,753 | +32.9% | 2024-12-31 |
Boothbay Fund Management, Llc | $18,789.00 | 2.04% | 1.29M | +304,065 | +30.91% | 2024-12-31 |
Stonepine Capital Management, Llc | $18,451.00 | 2.01% | 1.26M | -105,170 | -7.68% | 2024-12-31 |